FTLF FITLIFE BRANDS, INC. Insider Trading

Director Yakatan Seth buys 164 FTLF shares at $15.36; stock now $8.99. Cluster: 2 other insiders bought in past 14 days.

Director Yakatan Seth purchased 164 shares at $15.36 on January 15, 2026, increasing his holdings by 38.2% to 593 shares total. This purchase occurred as FITLIFE BRANDS stock trades 56.7% below its 52-week high of $20.76 and has fallen 45.0% over the past 90 days, creating a significant disconnect between the transaction price and current valuation. The transaction is notable because two other insiders also made purchases within the past 14 days, establishing a cluster buy pattern. While the company shows solid fundamentals with $23.5M quarterly revenue, 26.4% annual growth, and positive net income of $921.0K, investors should monitor whether this coordinated insider accumulation reflects confidence in a valuation reset or other strategic considerations not evident in public disclosures.

Director Dawson Grant Robert buys 3,000 shares at $9.98; stock down -55.4% from 52-week high.

Dawson Grant Robert, a director of FITLIFE BRANDS, INC. (FTLF), purchased 3,000 shares at $9.98 on 2026-04-10, growing his holdings to 158,000 shares. The transaction occurs against a steep backdrop of price deterioration: the stock is -55.4% from its 52-week high of $20.76 and down -39.2% over the past 90 days. Despite this weakness, the company shows underlying operational momentum with annual revenue growth of +26.4% and net income of $921,000 on quarterly revenue of $23.5M, trading at a P/E of 21.07. The buy itself is modest in scale—only 3,000 shares or +1.9% of his existing position—and no scheduled trading plan context is provided, so the purchase occurs against materially depressed valuation relative to prior-year highs. Investors should monitor whether this represents isolated opportunistic accumulation or the start of a pattern among insiders at a company experiencing significant stock-price pressure despite positive revenue and profit trends.

FTLF Director Lingenbrink bought 3,000 shares at $9.76; holdings now 8,800 shares; stock -55.4% from 52-week high.

Director Matthew Lingenbrink purchased 3,000 shares at $9.76, increasing his holdings by 51.7% to 8,800 shares. The purchase occurred against a backdrop of sharp recent weakness: the stock is down 55.4% from its 52-week high of $20.76 and has declined 32.9% over the past 30 days and 39.2% over 90 days. Lingenbrink's prior two purchases at FITLIFE BRANDS were both well-timed at the 90-day mark, with gains of 7.0% and 5.2% respectively; his cross-ticker track record shows 100% 90-day win rate across 2 buys. The company's fundamentals show revenue of $23,485,000.00 with net income of $921,000.00 and annual revenue growth of 26.4%, suggesting underlying operational strength despite the equity market deterioration. This combination—sustained insider buying during significant drawdown, consistent prior timing success at this ticker, and solid fundamental growth metrics—is notable, though current price weakness and recent volatility warrant monitoring of near-term momentum.

Director Ordal Todd bought 300 FTLF shares at $12.07; stock now $11.80, down 26.2% in 90 days, and his prior buy lost 59.6% over the same period.

Ordal Todd, a director, purchased 300 shares at $12.07 on 2025-04-15, increasing his holdings to 62,488 shares (+0.5% vs prior holdings). The stock has declined 26.2% over 90 days and is currently -32.6% from its 52-week high of $17.50, trading at $11.80. His prior purchase at this ticker (2025-01-15) lost 59.6% over 90 days, and his cross-ticker track record shows a 0% win rate on prior buys with an average 90-day return of -59.6%. The modest position size ($3.6K) and recent pattern of losses following insider purchases at FTLF provide limited confidence in favorable near-term outcomes.

Director Lingenbrink bought 3,000 shares of FTLF at $12.17, doubling position to 5,800 shares; stock down 32.6% from 52-week high.

Director Matthew Lingenbrink purchased 3,000 shares at $12.17 on 2025-04-14, increasing his holdings from 2,800 to 5,800 shares (+107.1%). The transaction value was $36,510.00. The buy occurred while FITLIFE BRANDS trades $11.80, down 32.6% from its 52-week high of $17.50 and off 13.7% in the prior 30 days. Fundamentals remain solid: the company posted quarterly revenue of $15,977,000.00 with net income of $2,126,000.00 and annual revenue growth of +22.3%, supported by a P/E of 9.01 and market cap of $108,778,630.40. Lingenbrink's prior transaction at this ticker occurred on 2025-03-31 (14 days earlier), indicating active engagement with the position over a compressed timeline.

Director Lingenbrink Matthew bought 2,800 shares of FTLF at $12.17 on 2025-03-31; stock down 29.7% from 52-week high.

Director Lingenbrink Matthew acquired an initial 2,800 shares at $12.17, representing his first shareholding in FITLIFE BRANDS, INC. The purchase occurs in a context of significant stock price weakness: the company trades at $12.30 (current price), down 29.7% from its 52-week high of $17.50 and off 18.5% over the past 30 days. Despite this price deterioration, FTLF maintains reasonable fundamental metrics—a P/E of 9.39, annual revenue growth of +22.3%, and positive quarterly net income of $2.1M on revenues of $16.0M. The entry by a director at a depressed valuation level warrants tracking of whether this represents a single opportunistic purchase or part of a broader accumulation pattern, particularly given the stock's recent momentum headwinds.

Director Ordal Todd bought 150 FTLF shares at $30.37; stock now $16.00, down 8.6% from 52-week high, +83% revenue growth YoY.

Ordal Todd, a director of FITLIFE BRANDS, purchased 150 shares at $30.37 on 2025-01-15, increasing his holdings from 30,944 to 31,094 shares. The purchase price of $30.37 significantly exceeds the current market price of $16.00, meaning the insider has an unrealized loss of approximately 47% on this transaction. The company shows strong fundamental momentum with annual revenue growth of +83.0% and a P/E of 8.74, suggesting the business is performing well operationally. However, the stock is down 8.6% from its 52-week high and -4.5% over 30 days, indicating recent market weakness that contrasts with the company's strong revenue trajectory and the insider's decision to deploy capital above current levels.